[Cell proliferation factors and vascular damage].
Block
L H
LH
Department of Medicine IV, University of Vienna, Austria.
Roth
M
M
D000077214:Becaplermin; D015152:Blotting, Northern; D015153:Blotting, Western; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D004095:Dihydropyridines / Q000494:pharmacology; D005920:Glomerular Mesangium / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000187:drug effects; D009578:Nitrobenzenes; D010879:Piperazines; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000032:analysis / Q000187:drug effects; D011973:Receptors, LDL / Q000032:analysis / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009578:Nitrobenzenes; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D011973:Receptors, LDL; D011994:Recombinant Proteins; D000077214:Becaplermin; C054218:manidipine